Q-omics provides the consensus-scored MIR548B profile across patient tissues and cancer cell-line models. MIR548B expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR548B is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, MIR548B RNA expression shows 9,681 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCS, KICH, and COAD as cancer lineages where MIR548B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548B survival associations across molecular data types. MIR548B RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548B RNA expression–survival associations across cancer types. High MIR548B expression shows unfavorable associations in UCS, UCEC, LUSC and BLCA, but favorable associations in KIRC and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR548B RNA expression.
This table summarizes MIR548B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548B shows lower tumor expression in KICH. The KICH box plot shows higher MIR548B RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p = .038).
This table shows molecular features associated with MIR548B in patient tissues and cancer cell lines. In patient samples, MIR548B shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
